New knee implant tested for Long-Term success
NCT ID NCT02380092
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study follows 163 people who received a LEGION knee replacement with a special VERILAST bearing surface to treat degenerative joint disease. Researchers track how long the implant lasts and how well patients function over time. The goal is to see if this newer device performs as well as or better than an older model.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- LEGION Primary Total Knee System with VERILAST bearing surface (a knee replacement device)
- What this could lead to
- If successful, this could confirm that the LEGION knee system is a safe and durable option for people needing knee replacement due to arthritis.
- What could go wrong
- This is a post-market study, not a new treatment. Results may not show major improvement over existing options, and some patients may still need revision surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
163 people
The number who actually took part.
- Started
-
Sep 2015
- Expected to finish
-
May 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Subjects who are scheduled to have Total Knee Arthroplasty with the Legion Primary Total Knee System due to Degenerative Joint Disease.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subject requires primary TKA and has elected to use the LEGION™ Primary TKS with VERILAST™. * Subject requires primary TKA due to degenerative joint disease (primary osteoarthritis, post-traumatic arthritis, avascular necrosis, rheumatoid arthritis). * Subject is of legal age to consent, agrees to consent to and to follow the study visit schedule (as defined in the study protocol and informed consent form), by signing the EC approved informed consent form. * Routine radiographic assessment is possible. * Subject plans to be available through ten (10) years postoperative follow-up. * Subject is 18-75 years of age at the time of surgery. Exclusion Criteria: * Age \> 75 years at the time of surgery. * Subjects with immunosuppressive disorders. * Subject has severe pronation of the ipsilateral foot or any other relevant clinical condition contributing to abnormal ambulation (including but not limited to ankle fusion, ankle arthroplasty, previous hip fracture, ipsilateral hip arthritis resulting in flexion contracture). * Subject has undergone a previous major surgery to the study knee (including osteotomy, fracture fix, medial or lateral ligament surgery). * Subject has active infection or sepsis (treated or untreated). * At the time of enrollment, subject has one or more of the following arthroplasties that are not fully healed and well-functioning, as determined by the Investigator: * Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty. * Contralateral primary total knee or unicondylar knee arthroplasty. * Subject has presence of malignant tumor, metastatic, or neoplastic disease. * Subject has conditions that may interfere with the TKA survival or outcome (i.e., Paget's or Charcot's disease, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease). * Subject has any acute or chronic morbidity of vascular origin that, in the opinion of the Investigator, is likely to compromise successful treatment or compliance to follow-up visits. * Subject has inadequate bone stock to support the device (severe osteopenia, family history of severe osteoporosis or osteopenia). * Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study. * Subject has a Body Mass Index (BMI) \>40.0. * Subject requires revision TKA. * Subject is expected to require bilateral TKA within 1 year following study knee replacement. * Subject does not understand the language used in the Informed Consent Form. * Subject is enrolled in another clinical study at the same time.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Degenerative joint disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AMEOS Klinikum Seepark Geestland
Langen, Kreis Geestland, 27607, Germany
-
CaritasKlinikum St. Joseph Saarbrücken-Dudweiler
Saarbrücken-Dudweiler, 66125, Germany
-
Evangelisches Krankenhaus Wien
Vienna, 1180, Austria
-
KniePraxis Prof. Dr. Tibesku
Straubing, 94315, Germany
-
OrthoCentrum
Hamburg, 20149, Germany
-
Orthopadische Krankenhaus Gersthof
Vienna, 1180, Austria
-
Servicio de C.O.T. Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, 15706, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New MRI study aims to better understand jaw joint disease
- Spray-on drug may cut blood loss in major spine surgery
- New shoulder implant under Long-Term watch: will it hold up?
- Hip replacement recovery: are old rules unnecessary?
- New hip implant aims to improve joint replacement outcomes
- Hidden joint pain in nursing homes revealed